Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial

OBJECTIVE: To test the hypothesis that ticagrelor plus aspirin is safe and superior to clopidogrel plus aspirin for reducing high platelet reactivity at 90 days and stroke recurrence in patients with minor stroke or transient ischaemic attack, particularly in carriers of the CYP2C19 loss-of-function...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:BMJ
Asıl Yazarlar: Wang, Yilong, Chen, Weiqi, Lin, Yi, Meng, Xia, Chen, Guohua, Wang, Zhimin, Wu, Jialing, Wang, Dali, Li, Jianhua, Cao, Yibin, Xu, Yuming, Zhang, Guohua, Li, Xiaobo, Pan, Yuesong, Li, Hao, Zhao, Xingquan, Liu, Liping, Lin, Jinxi, Dong, Kehui, Jing, Jing, Johnston, S Claiborne, Wang, David, Wang, Yongjun
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group Ltd. 2019
Konular:
Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6549283/
https://ncbi.nlm.nih.gov/pubmed/31171523
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmj.l2211
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller